Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)

Inclusion Criteria:

1. Aged >=18 years;
2. Novel coronavirus pneumonia patients diagnosed by pathogenic testing;
3. The patient himself participated in the study voluntarily, agreed and signed the informed consent.

Exclusion Criteria:

1. Meet the diagnostic criteria for severe new-type coronavirus infection pneumonia;
2. Severe primary diseases that affect survival, including: uncontrolled malignant tumors, hematological diseases, and HIV that have not been metastasized in multiple places;
3. Obstructive pneumonia, pulmonary interstitial fibrosis, alveolar proteinosis, and allergic alveolitis caused by lung tumors;
4. Women who are breastfeeding or pregnant;
5. Those who are known to be allergic to the ingredients contained in the research medication, or patients with allergies;
6. Those who have continued to use immunosuppressive agents or organ transplants in the past 6 months;
7. Patients who have participated in other drug clinical trials within 3 months before the screening test;
8. The investigator judges that he or she cannot complete or should not participate in the study (expected death within 48 hours, and the patient refuses active treatment)